Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 7/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | FYN | P06241 | 2/20 | 0.56 |
| ▸ | PRKACA | P17612 | 2/20 | 0.56 |
| ▸ | CSK | P41240 | 2/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.56 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.56 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964152 | 0.86 | SRC (0.66) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13019709 | 0.86 | SRC (0.73) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13019703 | 0.85 | SRC (0.65) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL1964244 | 0.85 | SRC (0.75) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL409554 | 0.85 | SRC (0.65) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL20805509 | 0.85 | SRC (0.46) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL3785884 | 0.85 | SRC (0.74) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL13063872 | 0.84 | SRC (0.66) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL7095503 | 0.81 | SRC (0.69) | SRCAKT1ABL1RIPK2PRKD3 | |
| SCHEMBL12551738 | 0.81 | SRC (0.69) | SRCAKT1ABL1RIPK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | SRC 3905/4885AKT1 4596/4885ABL1 2538/4885 |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | TSLP, NLRP3, IL1B | SRC 3970/4885AKT1 4799/4885ABL1 2987/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | SRC 303/4885AKT1 1695/4885ABL1 2453/4885 |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | TNF, TSLP, IL1B | SRC 3920/4885AKT1 4779/4885ABL1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.